1 September 2015 - Secukinumab (Cosentyx) was approved for use by adults with moderate to severe plaque psoriasis (psoriasis) in January 2015. The Institute for Quality and Efficiency in Health Care (IQWiG) has checked in a dossier evaluation whether this drug with respect to the appropriate comparator therapy offers an additional benefit. Such additional benefits, however, can not be inferred from the dossier: in patients for whom systemic therapy is eligible, an indirect comparison does not provide appropriate data because the minimum duration has not been reached. In adults, in whom other systemic therapies were unsuccessful or not appropriate, show the results of a direct comparison no statistically significant differences for the comparison group.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/secukinumab-bei-plaque-psoriasis-herstellerdossier-liefert-keinen-anhaltspunkt-fur-einen-zusatznutzen.6879.html?&et_cid=4&et_lid=%25208 [German]

MAESTrO Insight: Secukinumab (Cosentyx) was recommended by the PBAC on a cost-minimisation basis on March 2015 and was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 September 2015.